OTTAWA, May 7 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or
"the Company") today announced that the National Cancer Institute ("NCI") has
confirmed receipt of PharmaGap's drug product PhG-alpha-1 at its drug
depository in Rockville, MD, in advance of testing in the NCI's tumour cell
panel consisting of 60 human cancer cell lines. The NCI has advised the
Company that the results of the initial single dose test could normally be
expected in a minimum of six to ten weeks.
About The National Cancer Institute
The National Cancer Institute is an institute of the National Institutes
of Health, the primary U.S. Federal Agency for conducting and supporting
medical research. The NCI's mandate is to conduct and foster cancer research
in the United States, and is located in Bethesda, Maryland. For more
information please visit www.cancer.gov.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel therapeutic compounds for the
treatment of cancer. PharmaGap's research platform targets cellular signalling
pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug
compound, PhG-alpha-1, is in preclinical development. The Company's strategy
is to out-license drug compounds to larger life sciences companies at the
preclinical stage. For more information please visit www.pharmagap.com.
Note: The TSX-Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has approved or
disapproved of the information contained herein. This release contains forward
looking statements that may not occur or may change materially.
For further information:
For further information: Robert McInnis, President & CEO, (613)